Trulicity®
Dulaglutide is a once-weekly GLP-1 receptor agonist for type 2 diabetes. The molecule is fused to a modified IgG4 Fc fragment for extended half-life.
| Dosage Form | SC Injectable (Prefilled Pen / Autoinjector) |
| Strength | 0.75 mg, 1.5 mg, 3 mg, 4.5 mg |
| Storage | Store at 2–8°C. May be stored at room temperature (up to 30°C) for up to 14 days. |
| Category | Diabetes & GLP-1 |
| Availability | Available for Transfer |
Type 2 diabetes mellitus (adjunct to diet and exercise); reduction of MACE in adults with T2DM and established or multiple CVD risk factors.
GLP-1 receptor agonist linked to IgG4 Fc fragment. Activates GLP-1 receptors to stimulate insulin, suppress glucagon, and slow gastric emptying.
Each Burrard Pharmaceuticals technology transfer package for Dulaglutide includes comprehensive documentation and support:
Complete formulation with manufacturing parameters, excipient specifications, and process controls.
Validated methods for assay, impurities, dissolution, and stability-indicating analysis.
Market-ready regulatory dossier templates — available through Burrard Intelligence subscription.
ICH-compliant stability studies (accelerated and long-term) with detailed protocols.
Scale-up procedures, batch records, equipment specifications, and in-process controls.
Direct advisory access to formulation scientists and regulatory specialists throughout transfer.
Our team can deliver the complete know-how package within 2–21 business days. Book a consultation to discuss your specific requirements.